AZ, Merck match Clovis with Lynparza 'priority' boost in prostate cancer

21st January 2020 Uncategorised 0

After Clovis Oncology’s Rubraca snagged an FDA boost in prostate cancer last week, AstraZeneca and Merck’s rival Lynparza has matched it. The FDA bestowed its priority review designation on the PARP inhibitor for previously treated patients with metastatic, castration-resistant prostate cancer with certain genetic mutations.

More: AZ, Merck match Clovis with Lynparza 'priority' boost in prostate cancer
Source: fierce